Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.

Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM.

Breast Cancer Res Treat. 2012 Nov;136(1):153-60. doi: 10.1007/s10549-012-2243-x. Epub 2012 Sep 12.

PMID:
22968656
2.

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.

J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110.

PMID:
18413639
3.

Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.

Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS.

Chin J Cancer. 2010 Apr;29(4):413-9.

4.

The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.

Tarhan MO, Demir L, Somali I, Yigit S, Erten C, Alacacioglu A, Ellidokuz H, Seseogullari O, Kucukzeybek Y, Can A, Dirican A, Bayoglu V, Akyol M.

Clin Exp Metastasis. 2013 Feb;30(2):201-13. doi: 10.1007/s10585-012-9528-7. Epub 2012 Aug 23.

PMID:
22915160
5.

Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.

Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.

Eur J Surg Oncol. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10.

PMID:
23313014
6.

Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.

Jang G, Lee SS, Ahn JH, Jung KH, Lee H, Gong G, Kim HH, Ahn SD, Son BH, Ahn SH, Kim SB.

Breast Cancer Res Treat. 2011 Jul;128(1):171-7. doi: 10.1007/s10549-011-1526-y. Epub 2011 Apr 26.

PMID:
21519835
7.

Risk factors and survival outcome in cerebral metastatic breast cancer.

Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM.

Med Oncol. 2014 Mar;31(3):862. doi: 10.1007/s12032-014-0862-2. Epub 2014 Feb 7.

PMID:
24504842
8.

Brain metastases free survival differs between breast cancer subtypes.

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10.

9.

The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.

Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M.

J Neurooncol. 2013 May;112(3):467-72. doi: 10.1007/s11060-013-1083-9. Epub 2013 Mar 6.

PMID:
23462853
10.

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.

Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, Koh BS, Moon HG, You JH, Son BH, Ahn SH, Noh DY.

Breast Cancer Res Treat. 2011 Nov;130(2):499-505. doi: 10.1007/s10549-011-1736-3. Epub 2011 Aug 19.

PMID:
21853352
11.

Breast cancer subtypes and survival in patients with brain metastases.

Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J.

Breast Cancer Res. 2008;10(1):R20. doi: 10.1186/bcr1870. Epub 2008 Feb 28.

12.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
13.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481
14.

Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.

Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL.

J Clin Oncol. 2009 Oct 1;27(28):4701-8. doi: 10.1200/JCO.2008.21.7075. Epub 2009 Aug 31.

PMID:
19720911
15.

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.

Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28.

PMID:
19643597
16.

[Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].

Zhang T, Li Q, Xu B, Zhang P, Yuan P, Ma F, Wang J, Fan Y.

Zhonghua Zhong Liu Za Zhi. 2014 Sep;36(9):697-702. Chinese.

PMID:
25564062
17.

A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.

Chaiwun B, Nakrungsee S, Sukhamwang N, Srisukho S.

Breast Cancer. 2010;17(1):35-41. doi: 10.1007/s12282-009-0174-0.

PMID:
19789946
18.

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.

Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V.

Breast. 2006 Apr;15(2):219-25. Epub 2005 Jul 18.

PMID:
16026983
19.

Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.

Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS.

J Neurooncol. 2008 Jul;88(3):359-65. doi: 10.1007/s11060-008-9578-5. Epub 2008 Apr 9.

PMID:
18398574
20.

Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.

Yomo S, Hayashi M, Cho N.

J Neurooncol. 2013 Apr;112(2):199-207. doi: 10.1007/s11060-013-1046-1. Epub 2013 Jan 8.

PMID:
23296546

Supplemental Content

Support Center